Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

11.2K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
11.2K
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

7.7K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
7.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

247
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative outcomes of cryoextraction and conventional extraction in anterior and lateral orbitotomy for orbital cavernous venous malformations (so-called cavernous hemangioma).

BMC ophthalmology·2026
Same author

Functional assessment of the XEN<sup>®</sup> Gel Stent relative to the implant position using non-invasive stress testing and automated gonioscopy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Primary Orbital Extranodal NK/T-Cell Lymphoma: A European Case Report.

Case reports in ophthalmology·2026
Same author

On the crossroads of interdisciplinary medicine in amyloidosis - study protocol for a single-center interdisciplinary registry study.

PloS one·2026
Same author

THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.

Ophthalmology·2026
Same author

Prospective evaluation of patient reported outcome measures (PROMs) and correlation with clinical parameters of chronic ocular graft-versus-host disease (GVHD).

The ocular surface·2026

Related Experiment Video

Updated: Apr 14, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K

iStent inject in phakic open angle glaucoma.

Matthias K J Klamann1, Johannes Gonnermann, Milena Pahlitzsch

  • 1Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany, matthias@klamann.net.

Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie
|April 28, 2015
PubMed
Summary
This summary is machine-generated.

iStent inject implantation effectively lowers intraocular pressure and medication needs in primary open angle glaucoma (POAG) and pseudoexfoliation glaucoma (PEX). However, its efficacy in pigmentary glaucoma (PG) requires further investigation.

More Related Videos

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

4.5K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.8K

Related Experiment Videos

Last Updated: Apr 14, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K
Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
08:55

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

4.5K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.8K

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Medical Devices

Background:

  • Open-angle glaucoma encompasses several subtypes, each with unique characteristics.
  • The iStent inject is a micro-invasive device used to treat glaucoma.
  • Understanding the efficacy of iStent inject across different glaucoma subtypes is crucial for patient management.

Purpose of the Study:

  • To analyze the effectiveness of iStent inject implantation in various open-angle glaucoma subgroups.
  • To evaluate the complication profile of iStent inject in primary open angle glaucoma (POAG), pseudoexfoliation glaucoma (PEX), and pigmentary glaucoma (PG).

Main Methods:

  • A retrospective cohort study involving 35 glaucoma patients.
  • Patients were categorized into POAG (N=17), PEX (N=15), and PG (N=3) subgroups.
  • Intraocular pressure (IOP) and medication use were assessed pre- and post-surgery.

Main Results:

  • In POAG and PEX, iStent inject significantly reduced IOP by 33-35% and decreased medication use at 6 months (p<0.001).
  • In PG, initial IOP reduction was observed, but it increased within four weeks, necessitating further interventions.
  • Complications in PG subgroup suggested potential limitations of the device in this specific type of glaucoma.

Conclusions:

  • iStent inject implantation demonstrates significant IOP reduction and favorable outcomes in POAG and PEX at 6 months.
  • The device shows a favorable risk profile for POAG and PEX.
  • Potential limitations exist for iStent inject in phakic pigmentary glaucoma, warranting further research.